SG11201900201YA - Methods for quantitating individual antibodies from a mixture - Google Patents
Methods for quantitating individual antibodies from a mixtureInfo
- Publication number
- SG11201900201YA SG11201900201YA SG11201900201YA SG11201900201YA SG11201900201YA SG 11201900201Y A SG11201900201Y A SG 11201900201YA SG 11201900201Y A SG11201900201Y A SG 11201900201YA SG 11201900201Y A SG11201900201Y A SG 11201900201YA SG 11201900201Y A SG11201900201Y A SG 11201900201YA
- Authority
- SG
- Singapore
- Prior art keywords
- mixture
- international
- antibody molecule
- quantitating
- tarrytown
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
- 238000002169 hydrotherapy Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 ill HON HI 1 0 01111 VIII H I 11110 III OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/034885 Al 22 February 2018 (22.02.2018) WIP0 I PCT (51) International Patent Classification: (72) Inventors: LIU, Dingjiang; c/o Regeneron Pharmaceuti- A61K 39/395 (2006.01) C07K 16/00 (2006.01) cals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY BOLD 15/30 (2006.01) C07K 16/06 (2006.01) 10591 (US). LUO, Lin; c/o Regeneron Pharmaceuticals, (21) International Application Number: Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 PCT/US2017/045855 (US). XU, Long; Rm 501 No. 5 Ln 2059 Tongchuan Rd., Shanghai, 200333 (CN). (22) International Filing Date: (74) Agent: RUSSELL, Thara; Bookoff McAndrews, PLLC, 08 August 2017 (08.08.2017) 2401 Pennsylvania Avenue, NW, Suite 450, Washington, (25) Filing Language: English DC 20037 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/375,887 16 August 2016 (16.08.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: REGENERON PHARMACEUTICALS, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, NY 10591 (US). KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: METHODS FOR QUANTITATING INDIVIDUAL ANTIBODIES FROM A MIXTURE = = FIG. i — 0.048 - _ 0.044- I 1 I 0.040- 0.036 - 0.032- 0.09_8- = i A I l mAb A -- - mAb B __ _ cFDS mAb C = 0.024 _ — AU 0.020- - 0.016- = 0.012- = 0.008- = — M- O = I I \I - , ....... 0.000-'• -0.008- .. _ 0.00 280 4.00 6.U0 8.60 moo 1200 1480 16:00 18:00 20:00 22:00 24:00 2600 2800 30:00 32:00 34:00 3683 38:00 40:00 Minutes ti In (57) : The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture GO ot comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by il• hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each C antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the ---. mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on W D the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with 1-1 © little overlap from the other antibody molecules in the mixture, or both. ei C [Continued on next page] WO 2018/034885 Al MIDEDIMOMOIDEIREIHNIMIEHMOMEHOIS SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662375887P | 2016-08-16 | 2016-08-16 | |
PCT/US2017/045855 WO2018034885A1 (en) | 2016-08-16 | 2017-08-08 | Methods for quantitating individual antibodies from a mixture |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900201YA true SG11201900201YA (en) | 2019-02-27 |
Family
ID=59702834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900201YA SG11201900201YA (en) | 2016-08-16 | 2017-08-08 | Methods for quantitating individual antibodies from a mixture |
Country Status (14)
Country | Link |
---|---|
US (5) | US11020686B2 (en) |
EP (2) | EP4183414A1 (en) |
JP (2) | JP2019529350A (en) |
KR (3) | KR20230041834A (en) |
CN (1) | CN109641050A (en) |
AU (1) | AU2017312785A1 (en) |
BR (1) | BR112019000872A2 (en) |
CA (1) | CA3031742A1 (en) |
EA (1) | EA201990317A1 (en) |
IL (2) | IL309453A (en) |
MX (1) | MX2019000935A (en) |
MY (1) | MY196321A (en) |
SG (1) | SG11201900201YA (en) |
WO (1) | WO2018034885A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
CA3104390A1 (en) * | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
EP3886921A4 (en) * | 2018-11-30 | 2022-11-23 | Actinium Pharmaceuticals, Inc. | Antibodies conjugated with actinium-225 and actinium-227, and related compositions and methods |
MX2021008558A (en) * | 2019-01-16 | 2021-08-19 | Regeneron Pharma | Method and system of identifying and quantifying antibody fragmentation. |
KR20210134300A (en) | 2020-04-02 | 2021-11-09 | 리제너론 파아마슈티컬스, 인크. | Anti-SARS-COV-2 Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
CN114577885B (en) * | 2020-12-01 | 2024-03-29 | 齐鲁制药有限公司 | Method for detecting content proportion, charge heterogeneity and/or isoelectric point of recombinant combined antibody |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801726A (en) | 1986-04-15 | 1989-01-31 | Northeastern University | Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin |
US4937188A (en) | 1986-04-15 | 1990-06-26 | Northeastern University | Enzyme activity amplification method for increasing assay sensitivity |
US5190864A (en) | 1986-04-15 | 1993-03-02 | Northeastern University | Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material |
US5412083A (en) | 1992-04-16 | 1995-05-02 | Northeastern University | Carbohydrate heterobifunctional cross-linking reagent |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
AU4986596A (en) | 1995-02-16 | 1996-09-04 | Massachusetts Health Research Institute, Inc. | Purified tetanus toxoid and toxin |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
DE69922740T2 (en) | 1998-05-11 | 2005-12-08 | Tosoh Corp., Shinnanyo | Method for the separation of nucleic acids by liquid chromatography |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
DE60139944D1 (en) | 2000-10-12 | 2009-10-29 | Genentech Inc | LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS |
US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
US7101982B2 (en) | 2001-03-30 | 2006-09-05 | Immunex Corporation | Control of ph transitions during chromatography |
US20040106184A1 (en) | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
DK1545574T3 (en) | 2002-09-13 | 2014-09-08 | Biogen Idec Inc | PROCEDURE FOR CLEANING POLYPEPTIDES BY SIMULATED MOVING-BED CHROMATOGRAPHY |
SE0300612D0 (en) | 2003-03-05 | 2003-03-05 | Amersham Biosciences Ab | A method of preparing ligands for hydrophobic interaction chromatography |
US20060257972A1 (en) | 2003-03-31 | 2006-11-16 | Takashi Ishihara | Purification of human monoclonal antibody and human polyclonal antibody |
JP5068072B2 (en) | 2003-06-27 | 2012-11-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Modified binding molecule comprising a linking peptide |
EP1687328B1 (en) | 2003-10-24 | 2010-03-31 | Amgen, Inc. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
NZ548126A (en) | 2004-02-27 | 2009-10-30 | Ge Healthcare Bio Sciences Ab | A process for the purification of antibodies involving addition of a second resin |
SE0400501D0 (en) | 2004-02-27 | 2004-02-27 | Amersham Biosciences Ab | Antibody purification |
SE0400886D0 (en) | 2004-04-02 | 2004-04-02 | Amersham Biosciences Ab | Process of purification |
US7795405B2 (en) | 2004-08-09 | 2010-09-14 | Guild Associates, Inc. | Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis |
WO2006020622A1 (en) | 2004-08-09 | 2006-02-23 | Guild Associates, Inc. | Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis |
AU2005296352B2 (en) | 2004-10-21 | 2011-01-06 | Cytiva Bioprocess R&D Ab | Chromatography ligand |
EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
US20080299671A1 (en) | 2005-12-02 | 2008-12-04 | Ge Healthcare Bio-Sciences Ab | Hydrophobic Interaction Chromatography |
AU2007229554A1 (en) | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-IGF-1R human monoclonal antibody formulation |
CA2647029A1 (en) | 2006-04-05 | 2007-10-18 | Abbott Biotechnology Ltd. | Antibody purification |
KR101406811B1 (en) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | Vegf antagonist formulations suitable for intravitreal administration |
WO2008028974A1 (en) | 2006-09-08 | 2008-03-13 | Novo Nordisk A/S | Methods of optimizing chromatographic separation of polypeptides |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
WO2008079914A1 (en) * | 2006-12-21 | 2008-07-03 | Novartis Ag | Antibody quantitation |
US20080299545A1 (en) | 2007-03-06 | 2008-12-04 | Shuyuan Zhang | Chromatographic methods for assessing adenovirus purity |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
WO2009058769A1 (en) | 2007-10-30 | 2009-05-07 | Schering Corporation | Purification of antibodies containing hydrophobic variants |
NZ587161A (en) | 2008-01-25 | 2012-02-24 | Biogen Idec Inc | Automated system and and method for monitoring chromatography column performance by calculating performance parameters based on noise reduced process values |
DK2338049T3 (en) | 2008-08-15 | 2021-03-01 | Biogen Ma Inc | PROCEDURES FOR EVALUATION OF THE PERFORMANCE OF A CHROMATOGRAPHIC COLUMN |
US20100069617A1 (en) | 2008-09-12 | 2010-03-18 | Ge Healthcare Bio-Sciences Ab | Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions |
CN104974251A (en) | 2008-10-20 | 2015-10-14 | Abbvie公司 | Viral inactivation during purification of antibodies |
AU2009347206C1 (en) | 2008-10-20 | 2016-12-08 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
JP2012526121A (en) | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | Stable high protein concentration formulation of human anti-TNF alpha antibody |
MX352986B (en) | 2009-06-16 | 2017-12-15 | Genzyme Corp | Improved methods for purification of recombinant aav vectors. |
PL2459291T3 (en) | 2009-07-30 | 2018-07-31 | F.Hoffmann-La Roche Ag | Moveable chromatography column separator |
WO2011028961A2 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
EP2491055A2 (en) | 2009-10-20 | 2012-08-29 | Abbott Laboratories | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
US8246833B2 (en) | 2009-12-17 | 2012-08-21 | Ge Healthcare Bio-Sciences Ab | Chromatography column and maintenance method |
US20130131318A1 (en) | 2010-02-12 | 2013-05-23 | Diderik Reinder Kremer | Single unit antibody purification |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
EP2637690B1 (en) | 2010-11-11 | 2016-09-21 | AbbVie Biotechnology Ltd | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS |
AU2011343813B2 (en) | 2010-12-15 | 2015-05-21 | Takeda Pharmaceutical Company Limited | Eluate collection using conductivity gradient |
EP2500073A1 (en) | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
TWI589299B (en) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | Compositions for the treatment of rheumatoid arthritis and methods of using same |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
JP6435193B2 (en) * | 2011-10-19 | 2018-12-05 | ノビミューン エスアー | Methods for purifying antibodies |
EP2773439A4 (en) | 2011-10-31 | 2015-07-01 | Merck Sharp & Dohme | Chromatography process for resolving heterogeneous antibody aggregates |
DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
MX2014005885A (en) | 2011-11-21 | 2014-09-04 | Genentech Inc | Purification of anti-c-met antibodies. |
US9683012B2 (en) | 2011-12-15 | 2017-06-20 | Prestige Biopharma Pte. Ltd. | Method of antibody purification |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US20140154270A1 (en) | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
WO2013177115A2 (en) | 2012-05-21 | 2013-11-28 | Abbvie Inc. | Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
EP2879691B1 (en) | 2012-08-06 | 2019-03-27 | Biogen MA Inc. | Methods for inactivating enveloped viruses |
US9650411B2 (en) | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
CA2895198A1 (en) | 2012-12-20 | 2014-06-26 | Medimmune, Llc | Liquid antibody formulation with improved aggregation properties |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
RU2768003C2 (en) | 2013-03-08 | 2022-03-22 | Джензим Корпорейшн | Integrated continuous production of therapeutic protein-based medicinal agents |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
CA2918328C (en) * | 2013-03-13 | 2020-09-01 | Ibentrus, Inc. | Protein in which electrostatic interaction is introduced within hydrophobic interaction site and preparation method thereof |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
SG11201504260UA (en) | 2013-03-14 | 2015-10-29 | Abbvie Inc | Low acidic species compositions and methods for producing and using the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
JP6592426B2 (en) | 2013-03-15 | 2019-10-16 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Protein purification using hydrophobic interaction chromatography under salt-free conditions |
EP3754012A1 (en) | 2013-03-15 | 2020-12-23 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
CA2906022A1 (en) * | 2013-03-15 | 2014-09-25 | Abbvie Inc. | Antibody drug conjugate (adc) purification |
SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
TWI682780B (en) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | Use of a pharmaceutical composition for the manufacture of a medicament for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI697334B (en) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
KR101569783B1 (en) | 2013-06-05 | 2015-11-19 | 한화케미칼 주식회사 | A Method of Antibody Purification |
US9150938B2 (en) | 2013-06-12 | 2015-10-06 | Orochem Technologies, Inc. | Tagatose production from deproteinized whey and purification by continuous chromatography |
TWI596107B (en) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | Novel purification process for monoclonal antibodies |
MX2016002798A (en) | 2013-09-05 | 2016-07-21 | Genentech Inc | Method for chromatography reuse. |
EP3044323B1 (en) | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
MX2016003202A (en) | 2013-09-13 | 2016-06-07 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides. |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US20160251441A1 (en) | 2013-10-25 | 2016-09-01 | Medimmune, Llc | Antibody purification |
US10115576B2 (en) | 2013-12-12 | 2018-10-30 | Waters Technologies Corporation | Method and an apparatus for analyzing a complex sample |
JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
FR3025515B1 (en) | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | PROCESS FOR PURIFYING MONOCLONAL ANTIBODY |
AR102198A1 (en) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION |
EP3226899A4 (en) | 2014-12-02 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating dry eye disease by administering an il-6r antagonist |
EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
BR112018012929A2 (en) | 2015-12-22 | 2018-12-11 | Regeneron Pharma | bispecific anti-cd20 / anti-cd3 antibodies to treat acute lymphoblastic leukemia |
PT3394103T (en) | 2015-12-22 | 2023-09-04 | Regeneron Pharma | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
GB201602938D0 (en) | 2016-02-19 | 2016-04-06 | Ucb Biopharma Sprl | Protein purification |
CN109641928B (en) | 2016-06-14 | 2022-08-30 | 比奥根Ma公司 | Hydrophobic interaction chromatography for oligonucleotide purification |
WO2018027195A1 (en) | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
US10626376B2 (en) | 2016-11-14 | 2020-04-21 | St. Jude Children's Research Hospital | Method for isolating and purifying adeno-associated virus particles using salt |
EP3672981A4 (en) | 2017-08-22 | 2021-09-15 | Biogen MA Inc. | Methods for purifying antibodies having reduced high molecular weight aggregates |
WO2019178495A1 (en) | 2018-03-16 | 2019-09-19 | Biogen Ma Inc. | Methods for purifying recombinant adeno-associated viruses |
US20210010055A1 (en) | 2018-03-16 | 2021-01-14 | Bristol-Myers Squibb Company | Metabolic enzyme activity and disulfide bond reduction during protein production |
CN112313248A (en) | 2018-03-29 | 2021-02-02 | 百时美施贵宝公司 | Method for purifying monomeric monoclonal antibodies |
EP3810650A1 (en) | 2018-06-19 | 2021-04-28 | Bristol-Myers Squibb Company | Methods of purifying proteins using chromatography |
TW202005694A (en) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | Systems and methods for preparing a polypeptide from a mixture |
WO2020023566A1 (en) | 2018-07-25 | 2020-01-30 | Merck Sharp & Dohme Corp. | Methods of separating host cell lipases from a production protein in chromatographic processes |
JP2021534151A (en) | 2018-08-15 | 2021-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Protein fragmentation control strategy by reoxidation in downstream chromatography |
KR20210090649A (en) | 2018-11-05 | 2021-07-20 | 브리스톨-마이어스 스큅 컴퍼니 | Methods for Purification of PEGylated Proteins |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
US20220042954A1 (en) | 2019-03-29 | 2022-02-10 | Bristol-Myers Squibb Company | Methods of measuring hydrophobicity of chromatographic resins |
WO2020264411A1 (en) | 2019-06-28 | 2020-12-30 | Baxalta Incorporated | Adeno-associated virus purification methods |
-
2017
- 2017-08-08 AU AU2017312785A patent/AU2017312785A1/en active Pending
- 2017-08-08 WO PCT/US2017/045855 patent/WO2018034885A1/en unknown
- 2017-08-08 KR KR1020237008775A patent/KR20230041834A/en not_active Application Discontinuation
- 2017-08-08 KR KR1020227005544A patent/KR102511050B1/en active IP Right Grant
- 2017-08-08 BR BR112019000872-1A patent/BR112019000872A2/en unknown
- 2017-08-08 EP EP22208008.7A patent/EP4183414A1/en active Pending
- 2017-08-08 JP JP2019505225A patent/JP2019529350A/en active Pending
- 2017-08-08 IL IL309453A patent/IL309453A/en unknown
- 2017-08-08 MX MX2019000935A patent/MX2019000935A/en unknown
- 2017-08-08 SG SG11201900201YA patent/SG11201900201YA/en unknown
- 2017-08-08 EP EP17757957.0A patent/EP3500297A1/en not_active Withdrawn
- 2017-08-08 MY MYPI2021007750A patent/MY196321A/en unknown
- 2017-08-08 IL IL264631A patent/IL264631B1/en unknown
- 2017-08-08 US US16/322,292 patent/US11020686B2/en active Active
- 2017-08-08 KR KR1020197004613A patent/KR102369014B1/en active IP Right Grant
- 2017-08-08 EA EA201990317A patent/EA201990317A1/en unknown
- 2017-08-08 CN CN201780050583.0A patent/CN109641050A/en active Pending
- 2017-08-08 CA CA3031742A patent/CA3031742A1/en active Pending
-
2020
- 2020-10-21 US US17/076,307 patent/US11369896B2/en active Active
-
2021
- 2021-05-17 US US17/321,663 patent/US11571636B2/en active Active
-
2022
- 2022-08-04 JP JP2022124958A patent/JP2022159388A/en active Pending
- 2022-12-19 US US18/067,803 patent/US11850535B2/en active Active
-
2023
- 2023-08-30 US US18/458,482 patent/US20230415073A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102511050B1 (en) | 2023-03-17 |
CN109641050A (en) | 2019-04-16 |
IL264631A (en) | 2019-02-28 |
MY196321A (en) | 2023-03-24 |
IL264631B1 (en) | 2024-01-01 |
MX2019000935A (en) | 2019-07-04 |
US20230119592A1 (en) | 2023-04-20 |
US11020686B2 (en) | 2021-06-01 |
US11369896B2 (en) | 2022-06-28 |
US20190184312A1 (en) | 2019-06-20 |
JP2019529350A (en) | 2019-10-17 |
US20210268404A1 (en) | 2021-09-02 |
EP3500297A1 (en) | 2019-06-26 |
US11850535B2 (en) | 2023-12-26 |
US11571636B2 (en) | 2023-02-07 |
BR112019000872A2 (en) | 2019-04-30 |
EA201990317A1 (en) | 2019-07-31 |
CA3031742A1 (en) | 2018-02-22 |
US20210031123A1 (en) | 2021-02-04 |
KR20220025943A (en) | 2022-03-03 |
US20230415073A1 (en) | 2023-12-28 |
WO2018034885A1 (en) | 2018-02-22 |
AU2017312785A1 (en) | 2019-01-24 |
KR102369014B1 (en) | 2022-03-02 |
KR20190039144A (en) | 2019-04-10 |
KR20230041834A (en) | 2023-03-24 |
EP4183414A1 (en) | 2023-05-24 |
JP2022159388A (en) | 2022-10-17 |
IL309453A (en) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201908796XA (en) | Improved antigen binding receptors | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201408347UA (en) | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides | |
SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
SG11201809789SA (en) | Dna monoclonal antibodies targeting checkpoint molecules | |
SG11201907319QA (en) | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci |